Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 3Completed 3Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 11Lymphoma, Large B-Cell, Diffuse 10Triple Negative Breast Neoplasms 8Recurrence 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, B-Cell 6Neoplasm Metastasis 4Multiple Myeloma 4Leukemia, Myeloid, Acute 4Leukemia 4Neuroblastoma 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Hematologic Neoplasms 3Head and Neck Neoplasms 3Graft vs Host Disease 3Squamous Cell Carcinoma of Head and Neck 2Oropharyngeal Neoplasms 2Neoplasms, Plasma Cell 2Lymphoma, Follicular 2Hodgkin Disease 2Dendritic Cell Sarcoma, Interdigitating 2Carcinoma, Renal Cell 2Brain Neoplasms 2Wilms Tumor 1Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 2sargramostim 1iberdomide 1dinutuximab 1Topotecan 1Specimen Handling 1Cyclophosphamide 1Colony-Stimulating Factors 1Biopsy 13-fluorobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Ganglioneuroblastoma × Cyclophosphamide × Clear all
NCT07437963 2026-04-15

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
76 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡